AssetMark Inc’s Heron Therapeutics HRTX Stock Holding History

AssetMark Inc’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-33	Closed	-$1K	–	1353
2019 Q2	$1K	Buy	33 +11	+50%	+$220	﹤0.01%	1238
2019 Q1	$1K	Hold	22	–	–	﹤0.01%	1249
2018 Q4	$1K	Buy	+22	New	+$605	﹤0.01%	1315
2016 Q1	–	Sell	-16	Closed	–	–	1281
2015 Q4	$0	Buy	+16	New	+$428	﹤0.01%	1422

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AssetMark Inc's HRTX Position: Q3 2019 in Review

AssetMark Inc sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 33 shares — an estimated $1K sold.

AssetMark Inc first reported a position in HRTX in Q4 2015 and held it in 4 quarters. The position peaked at $1K in Q2 2019. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

AssetMark Inc reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
AssetMark Inc sold 33 Heron Therapeutics shares in Q3 2019, an estimated $1K.
AssetMark Inc first reported a position in Heron Therapeutics in Q4 2015 and held it in 4 quarters.
AssetMark Inc's Heron Therapeutics position peaked at $1K in Q2 2019.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on AssetMark Inc's 13F filing for Q3 2019, filed 13 Nov 2019.